Table 2.
Descriptive data for the 53 patients reported with rhabdomyolysis with azithromycin and statins
| Statin | Tot reports | No of. countries reporting | Age range | Dose range | Solely two drugs | Overlapping therapy of statins and azithromycin |
|---|---|---|---|---|---|---|
| Atorvastatin | 18 | 2 | 41–85 | 10–80 mg (n = 10) | 6 | 4 |
| Cerivastatin | 12 | 3 | 43–74 | 0.2–0.8 mg (n = 10) | 2 | 4 |
| Lovastatin | 2 | 1 | 51* | – | 0 | 0 |
| Pravastatin | 2 | 2 | 60–74 | 20 mg (n = 1) | 0 | 1 |
| Rosuvastatin | 4 | 2 | 59–82 | 10 mg (n = 2) | 0 | 2 |
| Simvastatin | 22 | 3 | 46–83 | 20–80 mg (n = 11) | 4 | 1 |
Age was provided in only one patient. n, the number of patients where dose information was provided.